New Research Reveals the Crucial Role of Endogenous Retrovirus Immunity in Tumor Immunity and Vaccine Development
A series of recent manuscripts by Skandorff et al., Daradoumis et al., and Ng et al. shed light on the significance of endogenous retrovirus immunity in tumor immunity and demonstrate our understanding of how to induce this immune response. These studies address a crucial dispute in retrovirology regarding the immunological importance of the immune suppressive […]
Hervolution receives 2.5M EUR in funding through the European Innovation Council Accelerator
We are beyond proud to announce that Hervolution is one of just 65 European companies to receive funding through the European Innovation Council Accelerator. Being selected among more than 4000 applicants, the funding of €2.5m
Hervolution announces the appointment of Jordi Naval as CEO, along with angel investment funding
Copenhagen, February 15th 2021 Hervolution Aps, a biotechnology company focused on developing breakthrough strategies for Immuno-oncology based on a new target class of endogenous retroviruses, today announced that it has appointed Jordi Naval as chief executive officer, along with undisclosed angel investment funding from Peter Elbæk and Johnny Henriksen. Naval is an accomplished biotech CEO […]
Dr. Martin Gleave joins Hervolution as scientific advisor
Hervolution is pleased to announce a new, exciting collaboration with Dr. Martin Gleave who joins the company as a scientific advisor. Dr. Gleave is a urologic surgeon and Distinguished Professor and Chair of the Department of Urologic Sciences at University of British Columbia, Canada. He is also co-founder and Executive Director of the highly respected […]
Postdoctoral grant allows Hervolution to engage in new exciting collaborations
Following the recruitment of Emeline Ragonnaud, who joined the team from NIH in June this year, Hervolution is now delighted to announce the award of a postdoctoral grant from Innovation Fund Denmark for her project. The grant has a 3-year perspective and allows Hervolution to establish strategic collaborations with key people within each of their […]
Hervolution attracts profile from NIH: Emeline Ragonnaud reunites with Peter J. Holst after 3 years
After spending 3 years in the US as a postdoctoral fellow at the National Institutes of Health (NIH), 32-year-old Emeline Ragonnaud has now moved to Denmark and joined Hervolution. But apart from being a story about an exceptional addition to the scientific team, this is also a story about a very special reunion. When Emeline […]
A family of research superstars: Hervolution’s founder is carrying on an impressive legacy
“I was in our sailboat with my dad. I think I was 8 or 9 years old. I asked him if anything exciting happened recently. He said he had discovered a new hormone which was to be called GLP-1.” The words belong to Hervolution’s founder, Peter Holst, who last weekend told his remarkable story in […]
CEO at SIRION, Christian Thirion, joins Hervolution as a Board Member
Hervolution is pleased to welcome Christian O. Thirion, Ph.D., who has joined the Board of Directors in February 2020. Christian is the founder and CEO of SIRION Biotech GmbH, a company that Hervolution recently entered into a partnership with. At SIRION, he has held multiple leadership positions and has been responsible for the scientific direction […]
Former F-star CEO joins Hervolution as strategic advisor
Hervolution can proudly welcome John Haurum, M.D., Ph.D. as a strategic advisor. John Haurum is a Non-executive Director in various European biotech companies, i.e. Synklino, Neophore, and Synact. From 2012 – 2018, Haurum was the CEO of F-star in Cambridge, UK, where he built a successful biotech company that initiated two clinical trials in oncology […]
SIRION Biotech Licenses Adenovirus Technology to Danish Startup, Hervolution for its Novel Immunotherapy Design Targeting Endogenous Retrovirus (ERV)
MUNICH & COPENHAGEN, February 4, 2020— SIRION Biotech GmbH (“SIRION”), a world leader in viral vector-based gene delivery technologies for gene and cell therapy, and Hervolution Aps (“Hervolution”), a Danish start up supported by Novo Nordisk Foundation’s BioInnovation Institute (BII), today announced a broad licensing agreement which includes coverage of SIRION’s adenovirus technologies to cancer […]
